TEVA Insider Trading Activity and SEC Form 4 Filings
TEVA insider trading summary
Over the past 12 months, insiders at Teva Pharmaceutical Industries Ltd (TEVA) reported 54 sales worth $98.5M by 15 insiders and no open-market purchases on SEC Form 4. Net insider selling was $98.5M.
Latest TEVA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 5, 2026 | Mark Sabag | See "Remarks" | Sell | $1.9M (46,000 @ $41.93) |
| Nov 4, 2026 | Dov Bergwerk | Interim Cheif Legal Officer | Sell | $730K (17,505 @ $41.72) |
| Nov 4, 2026 | Dov Bergwerk | Interim Cheif Legal Officer | Sell | $365K (8,755 @ $41.72) |
| Sep 18, 2026 | Brian Savage | Interim Chief Legal Officer | Sell | $12K (314 @ $38.70) |
| Sep 18, 2026 | Roberto Mignone | Insider | Sell | $14.4M (367,600 @ $39.06) |
| Sep 18, 2026 | Brian Savage | Interim Chief Legal Officer | Sell | $174K (4,503 @ $38.69) |
| Sep 18, 2026 | Brian Savage | Interim Chief Legal Officer | Sell | $99K (2,525 @ $39.15) |
| Aug 21, 2026 | Amir Weiss | Chief Accounting Officer | Sell | $94K (2,500 @ $37.63) |
| Aug 21, 2026 | Amir Weiss | Chief Accounting Officer | Sell | $261K (6,945 @ $37.61) |
| Aug 21, 2026 | Ronit Satchi-Fainaro | Insider | Sell | $15K (415 @ $37.25) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.